Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Elite just added a new jop opening
https://www.indeed.com/cmp/Elite-Pharmaceuticals,-Inc.-1/jobs
For the new facility
Elite will be first to market Generic OxyContin
$720 MILLION Market
This will blow this stock upward.
Locked and Loaded not chasing
GLTA
$10 bILLION combined IMS markets.
5% = $$ 500,000,000
7.5% = $$$$750,000,000
10% = $$$$$$1,000,000,000
Agree 100% as we painfully await the dry spell until 10K release end of June. What is a bit frustrating is that we don’t even have news/approvals for the smaller drugs and are kept in the dark. Looking forward to seeing first full Q with Prasco partnership for Q4 to get a taste of the financial benefit.
Good morning Namtae, low volume means very few want to trade this stock at the moment. Both shareholders and those short the stock are satisfied with their positions. As you know the price is based on supply and demand. Currently there is very little of either.
In the meantime cut and paste more pics of exotic autos, that will really convince every one on a penny stock MB that you're a big deal.
LOFL stop with the BS......OMG
Don't forget I'm here for you
Good morning James.
Curious why recent low volume equates to shareholders being happy with their ELTP positions
In a vacuum, low volume could suggest lack of sellers or lack of buyers.
Does your theory suggest shareholders were unhappy with their positions when ELTP fell from appx 21 cents to 13 on more active volume?
Does the 13 cent price coupled with low volume also suggest ELTP is now trading at fair value?
FWIW, right now I am neither a buyer nor a seller. I hold a large amount of shares (to me— I’m not a billionaire). My strong opinion is the shares will appreciate significantly. I’ve been around long enough to know I’m sometimes wrong. The low volume tells me I’m not the only one that is happy with their current position in ELTP. GLTA
More to come:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then LAUNCH
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__18. Generate revenues over $20 million/quarter
__19. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__20. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__21. European distribution - Dexcel partnership approval by Israeli Health
__22. Full ownership of Adderall IR $ 335 Million
__23. Full ownership of Adderall XR $ 1.56 Billion
__24. Generic Concerta- $1.2 BILLION FDA submission
__25. $100 million in yearly revenue
__26. Generic Vyvanse Approval and Launch
__27. $200 million in yearly revenue
__28. Deep pocket partner for SequestOx
__29. Patented Unique ADF (w/o naltrexone)-- NDA
__30. Mikah ANDA (s)
__31. Undisclosed ANDAs/NDAs
__32. DollarLand PPS
__33. Uplist to the NASDAQ Exchange
__34. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__35. Vegas Baby !!!!!!!
X 36. PE below 8.
Not when these peasants claim they can drop it more. It’s my millions of dollars and I’ll pick the price I want to..
The Liars, I mean Big Buyers must believe it will go even lower, or we would have seen some buying today !!!!!!!!!!!!!!
Hummmm,
LoL LoL
IB_🤴🏻
Disappointing...not one lottery dreamer could drop $15.00 at the close to go green and put some more lipstick on this pig.
I'm here for you !!!
Not sure how anyone buys or sells on days with volume like today.
I took on a few more. Still have $$ to buy more and more coming soon.
Locked $ Loaded
ELTP
Not worth the cost at this price?
Get to work! Drop the price so I can buy more. Work! Work!
Real barn burner so far, no interest at all.
Wait and watch the sell off when lottery club members get sick of the wait and need money for the next hype and hope dream.
The "rat" spoofed you, sorry to say, but it's time to be realistic about this thing....have a nice day.
I'm here for you
Just put him on ignore.
He will send a request from his fake hgils yahoo account begging to reply to his posts.
_ib despicable is his full name. Some say _ib stoopid lol
Because he’s a lawyer and the optics of that are beyond reasonable. One can talk their way out of Mikah winding down as things can change, but not a buyout like this. Not even 1% chance of this happening. If Nasrat went this route it would be an onslaught of legal pursuits against his decision making. Plus, all shareholders would have to approve. He has a real nice share, but not the majority to sway such a crappy decision.
I only object to idiotic ideas. There are plenty here. Mikah only gets part of profit split. Majority of revenue is from mfg fees, which Elite gets.
What makes you think he gives a day'um about how thing "look" ?????????????
Were we told years ago that Mikah was winding down operations,
IB_
No, Nasrat is chairman. That would look like a deal significantly in his favor with the pending filings with FDA. Not a chance even if premium at today’s prices.
She don't ...................
She is only the board contrarian & disagrees with everyone for entertainment,
IB_🤴🏻
Well, that's just a stupid statement !!!!!!!!!!!!!!!!!!!!!
Do you think Elite's Board of Directors would approve a buyout of Elite, by Mikah for $0.18 per share ??????????
Remember, as of today, that is a nice premium,
IB_🤴🏻
And you that how?
There’s no way Mikah can buy out Elite.
It exist !!!!!!!!!!!!!!!
I expect Mikah will be the future owners of Elite ..........................
Do you think Elites Board of Directors would approve the acquisition of ELTP by Mikah for the price of $0.20 per share ??????????
IB_🤴🏻
I’ll join you next time
Mikah ? Oh you mean the company that doesn’t exist anymore
How did that work out?
The CEO has been a great CEO for Mikah
Deserves substantial increase in salary for faking out Elite shareholders by filing Mikahs winding down and ceasing operations lol
If the CEO was an NFL player, hed be Barry Sanders
yOU GOT SPOOFED AT 2 CENTS A SHARE
and will be doinging it at 50 cents too, lmao
yOU SAID THAT AT 2 CENTS TOO, lol
Lottery club members were "spoofed" by Nasrat
When he impersonated a competent CEO.
My definition of spoofing is impersonation
Doubtful. Elite is not going to get involved in a big drawn out lawsuit if they expect to be bought out in a couple years. They want to prop up that Balance Sheet and not waste it on egregious legal fees.
Spoofing.....hyping and claiming this is worth more than 13 cents per share.
You have good tastes in transportation modes!
I expect Mikah may buy us out within 22 months, but truthfully, 22 months is just more silly babble .............................
Do they sell those cars in Thailand ????????????????
IB_🤴🏻
Shortages:
FDA shortage link
for Adderall:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
FDA shortage link for Methotrexate
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methotrexate%20Sodium%20Tablet&st=c
Bullish
Looking good going forward:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then Launch
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
X 18. PE ratio below 8
__19. Generate revenues over $20 million/quarter
__20. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__21. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__22. Legislation to make manufacturing generic drugs more profitable
__23. European distribution - Dexcel partnership approval by Israeli Health
__24. Full ownership of Adderall IR $ 335 Million
__25. Full ownership of Adderall XR $ 1.56 Billion
__26. Generic Concerta- $1.2 BILLION FDA submission
__27. $100 million in yearly revenue
__28. Generic Vyvanse Approval and Launch
__29. $200 million in yearly revenue
__30. Deep pocket partner for SequestOx
__31. Patented Unique ADF (w/o naltrexone)-- NDA
__32. Mikah ANDA (s)
__33. Undisclosed ANDAs/NDAs
__34. DollarLand PPS
__35. Uplist to the NASDAQ Exchange
__36. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__37. Vegas Baby !!!!!!!
I have a couple meetings with New Jersey based companies. I waiting for Elite to have that big partnership deal to bring them to the next level. Nasrat is the one to do it. Smart and steady hand driving the ship. Cheers.
Thank him for his awesome job!!!
Good
Morning. New Jersey. A great state to be in. I’m visiting today. Very nice maybe I’ll see Nasrat. Cheers.
After years of hyping ELTP, the truth finally came out !!!!!!!!!!!!!!!!!
IB_🤴🏻
I expect we will be worth whatever Mikah decides to offer !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Do you think Elite's Board of Directors will approve any offer that Mikah submits ?????????????????
IB_🤴🏻
$0.13 share price and pushing toward maxing out the authorized shares at almost 1,500,000,000 (1.5 BILLION) shares !!!!!!!!!!!
Do you think Elite's Board of Directors would approve an offer from Mikah for $0.20 per share ??????????? That is a premium,
IB_🤴🏻
Followers
|
967
|
Posters
|
|
Posts (Today)
|
91
|
Posts (Total)
|
402260
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators jimr1717 mrwrn2010 NASDAQ2020 IB_ namtae Dr JoeBarducci |
Elites 2024 "Official" Annual Revenue Guessing Game
Senior Moderator: IB_
Posted: 6/24/2024
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 53 | 55,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite |
Adderall XR | 1.56 B | On Market | 10 | Elite & Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 45 M | Approved (On Hold - Opioid) | 5 | ---------- |
Dopamine Agonist | 12 M | Filed with FDA - 22 Dec 2022 | ---------- | ---------- |
Methotrexate | 64.3M | Approved - 16 May 2024 | 8 | Elite |
Percocet | 500 M | Approved (On Hold - Opioid) | ---------- | |
Norco | 477 M | Approved (On Hold - Opioid) | ---------- | |
Methadone | 30 M | Approved (On Hold - Opioid) | ---------- | |
OxyContin | 720 M | Filed with FDA - 17 Aug 2023 | ---------- | ---------- |
Vyvanse | 5.1 B | Filed with FDA - 21 Dec 2023 | 14 | ---------- |
Concerta | 1.16 B | In Development (Final Stages) | 9 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 Q1 | 8,980,076 | +17.04% | 1,141,809 | +273.28% |
2024 Q2 | 14,157,185 | +64.90% | 14,934,601 | +866.0% |
2024 Q3 | 15,538,800 | +68.00% | 3,500,000 | +80.0% |
FY 2024 Projected | Minimum Projected: 50,000,000 | Minimum YOY Projected Increase of 68.31% | ||
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |